Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | IAPP | P10997 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849381 | 0.89 | CASP1 (0.39) | CASP1MAPK1CTSAKDM4EL3MBTL1 | |
| SCHEMBL2851181 | 0.89 | CASP1 (0.55) | CASP1SMN1; SMN2CYP1A2NPC1TP53 | |
| SCHEMBL2851376 | 0.82 | SCN9A (0.34) | MAPK1SMN1; SMN2CYP1A2NPC1TP53 | |
| SCHEMBL13500047 | 0.78 | CASP1 (0.40) | CASP1 | |
| SCHEMBL2859246 | 0.75 | CASP1 (0.57) | CASP1SMN1; SMN2CYP1A2MAPTGAA | |
| SCHEMBL15525179 | 0.74 | EGFR (0.45) | CASP1SMN1; SMN2NPC1TP53RAB9A | |
| SCHEMBL2849359 | 0.71 | ALDH1A1 (0.45) | MAPK1SMN1; SMN2CYP1A2NPC1TP53 | |
| SCHEMBL17144343 | 0.71 | NOTUM (0.46) | MAPK1SMN1; SMN2CYP1A2NPC1TP53 | |
| SCHEMBL30405765 | 0.71 | NOTUM (0.46) | MAPK1SMN1; SMN2CYP1A2NPC1TP53 | |
| SCHEMBL14556337 | 0.70 | PTPN1 (0.32) | MAPK1SMN1; SMN2CYP1A2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666883-B2 | 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-23 | — | — | US | claimed |
| EP-1924558-B1 | AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2010-01-13 | — | — | EP | claimed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | claimed |
| US-7666883-B2 | 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-23 | — | — | US | disclosed |
| US-7666883-B2 | 2-[(2-Chloro-5-methyl pyridine-3-yl)(hydroxy)methyl]acrylonitrile; against chloroquine sensitive and chloroquine resistant Plasmodium falciparum; treating malarial; chemical preparation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-02-23 | — | — | US | disclosed |
| EP-1924558-B1 | AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2010-01-13 | — | — | EP | disclosed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-05-24 | — | — | US | disclosed |
| WO-2007032016-A1 | AN ANTIMALARIAL BAYLIS-HILLMAN ADDUCTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117822-A1 | Novel antimalarial baylis-hillman adducts and a process for the preparation thereof | HBS1L, SSBP1, QARS1 | CASP1 931/4885MAPK1 2635/4885SMN1; SMN2 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.